592 research outputs found
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis
No full textCitation: Keiki Nagaharu, Eiko Ohya, Yoko Edahiro, Yoshinori Hashimoto, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito, Hideho Wada, Kensuke Usuki, Takayuki Tanaka, Takehiko Mori, Satoshi Wakita, Toshiki I. Saito, Akiko M. Saito, Kazuya Shimoda, Toshiro Kurokawa, Akihiro Tomita, Hitoshi Kiyoi, Koichi Akashi, Itaru Matsumura, Katsuto Takenaka, Norio Komatsu, Kohshi Ohishi, Isao Tawara, Yuka Sugimoto, Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis, Annals of Hematology, 103(9), 3535-3541, 2024-07-22, https://doi.org/10.1007/s00277-024-05898-
Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation
No full text金沢大学博士(医学）博士論文 要旨Abstract/本文Full 以下に掲載：Cell Death and Disease 14(9) pp.642-642 2023. Springer Nature. 共著者：Kenta Kurayoshi, Yusuke Takase, Masaya Ueno, Kumiko Ohta, Kyoko Fuse, Shuji Ikeda, Takayoshi Watanabe, Yuki Nishida, Shin-ichi Horike, Kazuyoshi Hosomichi, Yuichi Ishikawa, Yuko Tadokoro, Masahiko Kobayashi, Atsuko Kasahara, Yongwei Jing, Mahmoud I. Shoulkamy, Makiko Meguro-Horike, Kensuke Kojima, Hitoshi Kiyoi, Hiroshi Sugiyama, Hiroki Nagase, Atsushi Tajima and Atsushi Hiraodoctoral thesi
FLT3 Inhibitors: Recent Advances and Problems for Clinical Application
No full textFLT3, a type III receptor tyrosine kinase, expresses on most acute leukemia cells as well as normal hematopoietic stem/progenitor cells. Mutation in the FLT3 gene is the most frequent genetic alteration in acute myeloid leukemia (AML) and is well known as an important driver mutation for the development of myeloid malignancies. FLT3 mutation is a strong poor prognostic factor for the long-term survival in AML patients, while neither high-dose chemotherapy nor allogeneic hematopoietic stem cell transplantation can overcome a poor prognosis. Development of an FLT3 inhibitor is, therefore, much awaited. To date, several potent FLT3 inhibitors have been developed and some of them were evaluated for efficacy in clinical trials, although no FLT3 inhibitor has been yet approved. Moreover, several problems for clinical use, such as adverse effects, blood concentration and resistance have been apparent. Recently developed AC220 is a highly selective and sensitive FLT3 inhibitor. In Phase I and II trials, AC220 so far showed the best efficacy of AML cells harboring FLT3 mutation among clinically evaluated FLT3 inhibitors, while severe bone marrow suppression and QTc prolongation should be resolved for the clinical use. In this review, I summarize the characteristics of FLT3 inhibitors in clinical development and discuss important issues to be resolved for clinical use
FLT3 Inhibitors: Recent Advances and Problems for Clinical Application
No full text2015-02FLT3, a type III receptor tyrosine kinase, expresses on most acute leukemia cells as well as normal hematopoietic stem/progenitor cells. Mutation in the FLT3 gene is the most frequent genetic alteration in acute myeloid leukemia (AML) and is well known as an important driver mutation for the development of myeloid malignancies. FLT3 mutation is a strong poor prognostic factor for the long-term survival in AML patients, while neither high-dose chemotherapy nor allogeneic hematopoietic stem cell transplantation can overcome a poor prognosis. Development of an FLT3 inhibitor is, therefore, much awaited. To date, several potent FLT3 inhibitors have been developed and some of them were evaluated for efficacy in clinical trials, although no FLT3 inhibitor has been yet approved. Moreover, several problems for clinical use, such as adverse effects, blood concentration and resistance have been apparent. Recently developed AC220 is a highly selective and sensitive FLT3 inhibitor. In Phase I and II trials, AC220 so far showed the best efficacy of AML cells harboring FLT3 mutation among clinically evaluated FLT3 inhibitors, while severe bone marrow suppression and QTc prolongation should be resolved for the clinical use. In this review, I summarize the characteristics of FLT3 inhibitors in clinical development and discuss important issues to be resolved for clinical use.departmental bulletin pape
- …
